Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Sign up for Axios Pro Rata
Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Want a daily digest of the top Nashville news?
Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.
Want a daily digest of the top Columbus news?
Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.
Want a daily digest of the top Dallas news?
Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.
Want a daily digest of the top Austin news?
Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.
Want a daily digest of the top Atlanta news?
Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.
Want a daily digest of the top Philadelphia news?
Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.
Want a daily digest of the top Chicago news?
Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
Want a daily digest of the top DC news?
Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.
Sports stocks surged on Monday after Pfizer announced promising, though early, findings about the effectiveness of its COVID-19 vaccine.
Details: Live event stocks, which got crushed in the spring when sports and concert venues were shut down or left empty, were some of the biggest gainers.
- Live Nation, which owns Ticketmaster, jumped 23% midday to $68.87 — its largest one-day advance in at least 12 years. It closed at $64.36 (+14.85%).
The other side: Sports-related companies that benefit from people staying inside tumbled.
- Take-Two Interactive, which publishes the "NBA 2K" video game franchise, sank more than 8%.
- Collectors Universe, which saw its stock price jump this summer thanks to the trading card boom, plunged 10%.
The state of play: Pfizer says its vaccine was effective in over 90% of uninfected clinical trail patients.
- Still, "in the beginning, it is clear that there will be more limited distribution," CEO Albert Bourla said on Monday's Axios Re:Cap podcast.
- "50 million doses is 25 million people globally. Even if half goes to the U.S., that means that it's going to be 12 million people that we can protect in the next 1.5 months."
- "Very important protection, but still a small part of the population."
The big picture: Investors spent Monday buying into areas like live events and selling off hunker-at-home companies, "but the future is most likely to be a mixture of the old and the new," Axios' Dan Primack writes.
The bottom line: The Pfizer vaccine is a giant and welcome development, but it's not a silver bullet.
🎧 Listen: Full Bourla interview (Axios)